IKT – inhibikase therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Zacks Research to a "hold" rating.
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Form 4 Inhibikase Therapeutics, For: Nov 21 Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.
Form 8-K Inhibikase Therapeutics, For: Nov 20
Form 424B5 Inhibikase Therapeutics,
Form 424B5 Inhibikase Therapeutics,
Form 8-K Inhibikase Therapeutics, For: Nov 20
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.